Literature DB >> 10203868

Chimaeric G alpha proteins: their potential use in drug discovery.

G Milligan1, S Rees.   

Abstract

Approaches that allow ligand occupancy of a wide range of G protein-coupled receptors to be converted into robust assays amenable to relatively high-throughput analysis are ideal for screening for novel ligands at this class of receptor. Many attempts have been made to design universal ligand-screening systems such that any GPCR can be screened using a common assay end-point. Manipulation of the G protein within the assay system offers the possibility of achieving this. To better understand the domains involved in the interactions between G protein-coupled receptors, G proteins and effector polypeptides and the fine details of these contacts, a wide range of chimaeric G protein alpha subunits have been produced. Graeme Milligan and Stephen Rees discuss the information generated by such studies and the ways in which such chimaeric G proteins can be integrated into assay systems for drug discovery.

Mesh:

Substances:

Year:  1999        PMID: 10203868     DOI: 10.1016/s0165-6147(99)01320-6

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  12 in total

Review 1.  Exploring the dynamics of regulation of G protein-coupled receptors using green fluorescent protein.

Authors:  G Milligan
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

2.  Measurement of effects of antibiotics in bioluminescent Staphylococcus aureus RN4220.

Authors:  M Tenhami; K Hakkila; M Karp
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 3.  Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs).

Authors:  D C Teller; T Okada; C A Behnke; K Palczewski; R E Stenkamp
Journal:  Biochemistry       Date:  2001-07-03       Impact factor: 3.162

Review 4.  G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.

Authors:  Graeme Milligan
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

5.  Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα₁₃ and β-arrestin-2.

Authors:  Laura Jenkins; Elisa Alvarez-Curto; Kate Campbell; Sabrina de Munnik; Meritxell Canals; Sabine Schlyer; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

6.  Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

Authors:  Jorge D Brioni; Robert B Moreland; Marlon Cowart; Gin C Hsieh; Andrew O Stewart; Petter Hedlund; Diana L Donnelly-Roberts; Masaki Nakane; James J Lynch; Teodozyi Kolasa; James S Polakowski; Mark A Osinski; Kennan Marsh; Karl-Erik Andersson; James P Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-15       Impact factor: 11.205

7.  Docking of human rhodopsin mutant (Gly90→Asp) with beta-arrestin and cyanidin 3-rutinoside to cure night blindness.

Authors:  Shagufta Kanwal; Sumaira Nishat; Muhammad Irfan Khan
Journal:  Bioinformation       Date:  2012-02-03

8.  Antagonists of GPR35 display high species ortholog selectivity and varying modes of action.

Authors:  Laura Jenkins; Nicholas Harries; Jennifer E Lappin; Amanda E MacKenzie; Zaynab Neetoo-Isseljee; Craig Southern; Edward G McIver; Stuart A Nicklin; Debra L Taylor; Graeme Milligan
Journal:  J Pharmacol Exp Ther       Date:  2012-09-11       Impact factor: 4.030

9.  Neuropeptide GPCRs in C. elegans.

Authors:  Lotte Frooninckx; Liesbeth Van Rompay; Liesbet Temmerman; Elien Van Sinay; Isabel Beets; Tom Janssen; Steven J Husson; Liliane Schoofs
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-21       Impact factor: 5.555

10.  The analysis of heterotaxy patients reveals new loss-of-function variants of GRK5.

Authors:  Davor Lessel; Tariq Muhammad; Teresa Casar Tena; Barbara Moepps; Martin D Burkhalter; Marc-Phillip Hitz; Okan Toka; Axel Rentzsch; Stephan Schubert; Adelheid Schalinski; Ulrike M M Bauer; Christian Kubisch; Stephanie M Ware; Melanie Philipp
Journal:  Sci Rep       Date:  2016-09-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.